Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of β-lapachone

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8866-8871

  Park, Heon Joo ^a,b   Choi, Eun Kyung ^c   Choi, Jihyung ^a   Ahn, Ki Jung ^a   Kim, Eun Jung ^b   Ji, In Mi ^b   Kook, Yeon Hee ^b   Ahn, Seung Do ^c   Williams, Brent ^a   Griffin, Robert ^a   Boothman, David A ^d   Lee, Chung K ^a   Song, Chang W ^a,e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Inha University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LAPACHONE; BETA TUBULIN; PROTEIN NQO1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMISTRY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CELL DEATH; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME REGULATION; FIBROSARCOMA; HEAT TOLERANCE; HYPERTHERMIA; IMMUNOFLUORESCENCE MICROSCOPY; INCUBATION TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DICUMAROL; ENZYME INHIBITORS; HUMANS; HYPERTHERMIA, INDUCED; MICE; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; NEOPLASMS; UP-REGULATION;

EID: 29344464073     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0818     Document Type: Article

References (49)

1. Begleiter A, Fourie J. Induction of NQO1 in cancer cells. Methods Enzymol 2004;382:321-51.
2. Joseph P, Xie T, Xu Y, et al. NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase): expression, regulation, and role in cancer. Oncol Res 1994;6:525-32.
3. Joseph P, Jaiswal AK. NAD(P)H: quinone oxidoreductase I (DTdiaphorase) specifically prevents the formation of benzo(a)pyrene quinone-DNA adducts generated cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci U S A 1994;91:8413-7.
4. Rauth AM, Goldberg Z, Mirsa V. DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. Oncol Res 1997;9:339-49.
5. Begleiter A, Leith MK, Thlivenis JA, et al. Dietary induction of NQO1 increases the antitumor activity of mitomycin C in human colon tumor In vivo. Br J Cancer 2004:91:624-31.
6. Ross D, Siegel D. NAD(P)H: quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004;382:115-44.
7. Talalay P. Mechanisms or induction of enzymes that protect against chemical carcinogenesis. Adv Enzyme Regul 1989;28:149-59.
8. 5 reductase. Cancer Res 1993;53:4907-12.
9. Main A, Lopez de Cerain A, Hamilton E, et al. DT-diaphorase and cytochrome b5 reductase in human lung and breast tumors. Br J Cancer 1997;76:923-9.
10. Talalay P, Dinkova-Kostova AT. Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. Methods Enzymol 2004;382:355-67.
11. Siegel D, Beall H, Senekowitach C, et al. Bioreductive activation of mitomycin C by DT-diaphorase. Biol Chem 1992;31:7879-85.
12. Paull K, Camalier R, Fitzsimmons SA, et al. Correlations of DT-diaphorase expression with cell sensitivity data obtained from the NCI human tumor cell line panel. Proc Am Assoc Cancer Res 1994;35:369.
13. Watanabe N, Forman HJ. Autoxidation of extracellular hydroquinones is a causative event for the cytotoxicity of menadione and DMNQ in A549-S cells. Arch Biochem Biophys 2003;411:145-57
14. Pardee AB, LiY Z, Li C. Cancer therapy with β-lapachone. Curr Cancer Drug Targets 2002;2:227-42.
15. Gupta D, Podar K, Tai Y, et al. β-Lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol 2002;30:711-20.
16. Li YZ, Li CJ, Yu D, et al. Potent induction of apoptosis by β-lapachone in human multiple myeloma cell lines and patient cells. Mol Med 2000;6:1008-15.
17. Dubin M, Fernandezb Villamil SH, Stoppani AO. Cytotoxicity of β-lapachone, an naphthoquinone with possible therapeutic use. Medicina (B Aires) 2001;61: 343-50.
18. Planchone SM, Wuerzberger S, Frydman B, et al. β-Lapachone-mediated apoptosis in human promyelocytic leukemia 9 (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res 1995; 55:3706-11.
19. Li CJ, Wang C, Pardee AB. Induction of apoptosis by β-lapachone in human prostate cancer cells. Cancer Res 1995;55:3712-5.
20. Lai CC, Lui TJ, Ho LK, et al. β-Lapachone induced cell death in human hepatoma (HepA2) cells. Histol Histopathol 1998;13:89-97.
21. Planchone SM, Pink JJ, Tagliarino C, et al. β-Lapachone-induced apoptosis in human prostate cancer cells: involvement of Nqo/xip3. Exp Cell Res 2001; 267:95-06.
22. Pink JJ, Planchone SM, Tagliarino C, et al. NAD(P)H:quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity. J Biol Chem 2000;275:5416-24.
23. Pink JJ, Wuerzberger-Davis S, Tagliarino C, et al. Activation of cysteine protease in MCF-7 and T47D breast cancer cells during β-lapachone mediated apoptosis. Exp Cell Res 2000;25:144-55.
24. Tagliarino C, Pink JJ, Dubyak GR, et al. Calcium is a key signaling molecule in β-lapachone mediated cell death. J Biol Chem 2001;276:19150-9.
25. Wuerzberger SM, Pink JJ, Planchon SM, et al. Induction of apoptosis in MCF-7:WS8 breast cancer cells by β-lapachone. Cancer Res 1998;58:1876-85.
26. Miyamoto S, Huang TT, Wuerzberger-Davis S, et al. Cellular and molecular responses to topoisomerase I poisons: exploiting synergy for improved radiotherapy Ann N Y Acad Sci 2000;922:274-92.
27. Boothman DA, Pardee AB. Inhibition of radiation-induced neoplastic transformation by β-lapachone. Proc Natl Acad Sci U S A 1989;86:4963-7.
28. Hueber A, Esser P, Heimann K, et al. The topoisomerase I inhibitors, camptothecin and β-lapachone, induce apoptosis of human retinal pigment epithelial cells. Exp Eye Res 1998:67:525-30.
29. Li CJ, Averboukh L, Pardee AB. β-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem 1993;268:22463-8.
30. Weeler M, Winter S, Schmidt C, et al. Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bel-2 expression and of CD95-mediated apoptosis by camptothecin and β-lapachone. Int J Cancer 1997;73:707-14.
31. Furuya Y, Ohta S, Ito H. Apoptosis and androgen-independent mammary and prostate cell lines induced by topoisomerase inhibitors: common pathways of gene regulation. Anticancer Res 1997;17:2089-93.
32. Frydman B, Marton LJ, Sun JS, et al. Induction of DNA topoisomerase II-mediated DNA cleavage by β-lapachone and related naphthoquinones. Cancer Res 1997;57:620-7.
33. Krishnan P, Bastow KF. Novel mechanism of cellular DNA topoisomerase II inhibition by the pyranonaphthoquinone derivatives α-lapachone and β-lapachone. Cancer Chemother Pharmacol 2001;47:197-8.
34. Li Y, Li CJ, Yu D, et al. Potent induction of apoptosis by β-lapachone in human multiple myeloma cell line and patient care. Mol Med 2000;6:1008-15.
35. Li Y, Sun X, La Mont JT, et al. Selective killing of cancer cells by β-lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci U S A 2003;100:2674-8.
36. Li CJ, Li YZ, Pinto AV, et al. Potent inhibition of tumor survival in vivo by β-lapachone plus Taxol: combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci U S A 1999;96:13369-74.
37. Tagliarino C, Pink JJ, Boothman DA. Calpains and apoptosis. Korean J Biol Sci 2001;5:267-74.
38. Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase. Cancer Res 1989;49:605-12.
39. Boothman DA, Greer A, Pardee AB. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by β-lapachone (3,4-dihyrdro-2,2-dimethyl-2H-naptho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res 1987;47:5361-6.
40. Park HJ, Ahn KJ, Ahn SD, et al. Susceptibility of cancer cells to β-lapachone is enhanced by ionizing radiation. Int J Radiat Oncol Biol Phys 2005;61:212-9.
41. Nasongkla N, Wiedmann AF, Bruening A, et al. Enhancement of solubility and bioavailability of β-lapachone using cyclodextrin inclusion in complexes. Pharm Res 2003;20:1626-33.
42. Ahn KJ, Lee CK, Choi EK, et al. Cytotoxicity of perillyl alcohol against cancer cells is potentiates by hyperthermia. Int J Radiat Oncol Biol Phys 2003;57: 813-9.
43. Winski SL, Swann E, Hargreaves RHJ, et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 2001;61:1509-16.
44. Ogawa A, Griffin RJ, Song CW. Effects of combination of mild temperature hyperthermia and nicotinamide on radiation response of experimental tumours. Radiat Res 2000;153:327-31.
45. Griffin RJ, Lee SH, Rood LK, et al. Use of arsenic trioxide as an anti-vascular and thermosensitizing agent in solid tumors. Neoplasia 2001;2:555-60.
46. Boothman DA, Meyers M, Fukunaga S, et al. Isolation of X-ray-inducible transcripts from radioresistant melanoma cells. Proc Natl Acad Sci U S A 1993;90: 7200-4.
47. Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 1998;4: 2065-70.
48. Belinsky M, Jaiswal AK. NAD(P)H: quinone oxidoreductase 1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993;12:103-17.
49. Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 1991;42:1021-7.